Globalpharma slashes carbon emissions by 11,400 tonnes
Globalpharma has successfully reduced its overall carbon footprint by approximately 11,400 tonnes of CO₂.
This substantial reduction in greenhouse gas emissions was achieved through the strategic installation of a 612 kWp (kilowatt-peak) rooftop solar photovoltaic (PV) system. Located at the company’s primary manufacturing facility within the Dubai Investments Park (DIP), the extensive solar array represents a definitive step towards fostering a highly sustainable industrial landscape in the region.
The newly integrated system is expected to generate approximately 25.3 GWh (Gigawatt-hour) of clean, renewable energy. This substantial electrical output actively supports improved energy efficiency across the entire manufacturing plant while drastically reducing the company's historical reliance on grid-supplied electricity. The advanced rooftop installation was meticulously developed in close collaboration with 386 Sky Solar Energy Systems LLC. This partnership effectively brings together Globalpharma's dedicated focus on operational optimisation with the specialised expertise required for industrial-scale renewable energy deployment.
Strategic export through the Shams Dubai Programme
The expansive solar installation has been officially implemented under the regulatory framework of Dubai's Shams Dubai programme. This progressive governmental initiative enables both direct on-site energy consumption and the continuous export of surplus power to the municipal grid through a highly efficient bi-directional metering system. Ultimately, the project represents a significant step in integrating clean energy within Globalpharma's daily manufacturing operations while simultaneously enhancing operational performance.
The leadership at Globalpharma views this milestone as a core component of their long-term corporate strategy. Commenting on the initiative, Dr. Basem Albarahmeh, Chief Executive Officer of Globalpharma, said: “This initiative builds on a broader set of measures we have been implementing to strengthen efficiency and sustainability across our manufacturing operations. The integration of solar energy is a natural extension of our efforts to optimise resource utilisation, enhance energy efficiency and progressively reduce the environmental footprint of pharmaceutical production. As we continue to scale our capabilities, our focus remains on embedding sustainable practices within core operations, supporting a more resilient and future-ready manufacturing platform that aligns with evolving industry and regulatory expectations.”
Aligning with the UAE’s Net Zero 2050 Vision
The collaborative nature of the project also highlights the vital role of dedicated partnerships in achieving climate objectives. Commenting on the partnership, Ahmad Al Khayyat, Chairman of Three Eight Six, said: "Partnership is a statement of intent. Global Pharma has chosen to embed clean energy" into their manufacturing operations, and that is exactly the kind of leadership that moves an entire industry forward. UAE's Net Zero ambition will be built on decisions like this one."
This healthcare initiative aligns seamlessly with broader national priorities, including the UAE's ongoing clean energy transition and the comprehensive Net Zero 2050 strategy. It provides crucial support for the progressive decarbonisation of industrial operations within the healthcare manufacturing sector.
A legacy of growth and infrastructure
The successful implementation of this solar project reflects the enduring growth of Globalpharma. Established in 1998, the company is currently a market leader in key generic pharma segments with a strong regional footprint. The organisation officially started its operations in the UAE in 2003 and subsequently expanded its growth in 2008 with vital product line extensions and new product launches across fourteen countries in the GCC and select African markets.
Globalpharma actively operates two distinct manufacturing plants. The first is a state-of-the-art Beta-Lactam Penicillin manufacturing plant providing the Amoxicillin and AmoxiClav brands in the larger MENA region. Additionally, catering specifically to the lifestyle disease segments, the company runs a separate General Medicine manufacturing plant equipped with a variety of Liquid and Oral Solid Dose capabilities.
Facilitating this transition, 386 Sky Solar Energy Systems LLC is a prominent UAE-based Commercial and Industrial solar energy company. The firm delivers customised rooftop, ground-mount, and carport solar solutions across the GCC, directly helping businesses transition to clean energy in strict line with the UAE's Net Zero 2050 vision.